Medtronic Continues To Run (RNA) Interference With Alnylam
This article was originally published in The Pink Sheet Daily
Executive Summary
Device firm is upping its investment in biotech drug delivery by expanding its collaboration with Alnylam for development of an RNA-based treatment for Huntington’s disease.